Today's Trend
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) — The stock is down after a flurry of analyst revisions from William Blair following the company’s recent quarter (Q3) results that missed estimates. William Blair cut several near‑term EPS forecasts (FY2025/FY2026 and multiple quarters) while modestly raising a couple of longer‑range estimates; the mix of downgrades to near‑term profitability is weighing on the share price. Below are the actionable items investors should note.
- William Blair nudged up its Q4 2026 EPS forecast (to ($0.40) from ($0.42)) and raised its FY2027 EPS view (to ($1.53) from ($1.69)), signaling slightly better longer‑term expectations. MarketBeat AVIR
- Q3 2025 earnings call transcript is available for investors who want management’s commentary on pipeline progress and cash/runway items; useful for assessing whether operational updates mitigate near‑term forecast cuts. Earnings Call Transcript
- Press coverage of the earnings call highlights management’s tone of progress and optimism on programs — this narrative could support sentiment if the company delivers subsequent clinical or data milestones. MSN: Earnings Call Highlights
- William Blair cut multiple near‑term estimates: Q4 2025 from ($0.43) to ($0.53); Q1 2026 to ($0.53) from ($0.43); Q2 2026 to ($0.52) from ($0.42); Q3 2026 to ($0.46) from ($0.43); and trimmed FY2025 and FY2026 (both now deeper losses at ~($1.90) and ($1.90)). These downgrades reflect weaker near‑term profitability expectations and are likely the primary driver of the negative price reaction. MarketBeat AVIR
What to watch: upcoming clinical/data milestones, cash runway updates, or any guidance from management that could reverse the near‑term estimate cuts. Analysts’ revisions and continued earnings misses are the immediate bearish catalysts; positive clinical news would be the clearest path to reversing sentiment.